

Yazmin Odia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8905476/publications.pdf>

Version: 2024-02-01

26
papers

366
citations

1162889

8
h-index

839398

18
g-index

26
all docs

26
docs citations

26
times ranked

641
citing authors

#	ARTICLE	IF	CITATIONS
1	Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. <i>Neurology</i> , 2022, 98, .	1.5	6
2	Relationship between insurance status and interhospital transfers among cancer patients in the United States. <i>BMC Cancer</i> , 2022, 22, 121.	1.1	3
3	Malignant Glioma Subset from Actuate 1801: Phase \hat{A} 1/2 Study of 9-ING-41, GSK-3 \hat{I} 2 Inhibitor, Monotherapy or Combined with Chemotherapy for Refractory Malignancies. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac012.	0.4	2
4	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, 1366-1374.	0.6	36
5	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. <i>Scientific Reports</i> , 2022, 12, 4567.	1.6	8
6	Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. <i>Cancers</i> , 2022, 14, 2946.	1.7	2
7	Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 47-53.	0.8	5
8	Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab010.	0.4	15
9	Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. <i>Current Oncology</i> , 2021, 28, 1537-1543.	0.9	4
10	SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. <i>Neuro-Oncology</i> , 2021, 23, 1845-1858.	0.6	8
11	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, iii15-iii16.	0.4	0
12	Chemotherapy-induced changes in tumor consistency can allow gross total resection of previously unresectable brainstem pilocytic astrocytoma. , 2021, 12, 12.		0
13	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. <i>Discover Oncology</i> , 2021, 12, 48.	0.8	7
14	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab166.	0.4	5
15	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. <i>Scientific Reports</i> , 2021, 11, 22152.	1.6	3
16	Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 806-812.	0.6	2
17	A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1529-1535.	1.0	2
18	Early imaging marker of progressing glioblastoma: a window of opportunity. <i>Journal of Neuro-Oncology</i> , 2020, 148, 629-640.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	1.4	125
20	EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host. <i>Neurology: Clinical Practice</i> , 2019, 9, 456-458.	0.8	0
21	Electrographic Correlates of Plateau Waves in Patients With Leptomeningeal Metastases. <i>Neurohospitalist, The</i> , 2016, 6, 161-166.	0.3	14
22	A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 127-135.	1.4	35
23	A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. <i>CNS Oncology</i> , 2016, 5, 59-67.	1.2	21
24	A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 125, 191-195.	1.4	40
25	Isolated neurosarcoidosis presenting with recurrent hydrocephalus. <i>Neuroimmunology and Neuroinflammation</i> , 2015, 2, 287.	1.4	3
26	Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. <i>Journal of Neuro-Oncology</i> , 2014, 120, 431-440.	1.4	17